We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Key Patent of Protagen Granted in Japan

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Key Patent of Protagen Granted in Japan"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, has announced that it has received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany.

This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

Protagen is the exclusive licensee of the Max-Planck Society to commercialize the UNIclone® technology platform which serves the needs of modern proteomic analysis, to support in-vitro and companion diagnostic R&D projects (UNIarray®), and to provide antibody profiling tools (UNIchip®) for selection of therapeutic antibodies. One of the world largest selection of human recombinant proteins expressed in E.coli represents more than 10,000 human genes, and is in the possession of Protagen. For the full exploitation of this platform, Protagen has developed a proprietary high-throughput workflow for production and application of protein microarrays.

“This notice of allowance further strengthens our leading position in the area of protein arrays and diagnostic marker discovery in general. In particular, it supports our leading position in the determination of indication-specific autoantibody patterns for the development of novel serum based in-vitro diagnostics”, underscores Dr. Stefan Mullner, Chief Executive Officer of Protagen.

The technology is currently used in the internal research and development programs for early detection and diagnosis of cancer, auto-immune and neurological diseases as well as in cooperation with biopharmaceutical companies worldwide.